Jessica T Peters1, Candice L Garwood, Marybeth Lepczyk. 1. Department of Pharmacy Practice, Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, Michigan 48201, USA.
Abstract
BACKGROUND: There have been a number of published reports of central nervous system (CNS) adverse effects with statins. CASE SUMMARY: A 79-year-old woman developed paranoia, anxiety, and behavioral changes approximately 2.5 weeks after starting atorvastatin 10 mg/d. The patient had no other medication changes at this time. After 2 months of therapy, the patient discontinued atorvastatin, and her symptoms fully resolved after 4 days. CONCLUSIONS: This is the first case report, to our knowledge, describing paranoia as one of the symptoms associated with statin therapy. Our report suggests an adverse reaction due to the initiation of atorvastatin via the temporal relationship between the start of atorvastatin and symptom onset, as well as termination of therapy and subsequent symptom disappearance. Use of the Naranjo adverse drug reaction probability scale to assess causality revealed a "probable" association (score, 5) for this adverse event. This report emphasizes the possibility of paranoia as a CNS adverse effect due to statin therapy. Statins are frequently used in older populations and should therefore be considered when such CNS adverse effects occur during therapy.
BACKGROUND: There have been a number of published reports of central nervous system (CNS) adverse effects with statins. CASE SUMMARY: A 79-year-old woman developed paranoia, anxiety, and behavioral changes approximately 2.5 weeks after starting atorvastatin 10 mg/d. The patient had no other medication changes at this time. After 2 months of therapy, the patient discontinued atorvastatin, and her symptoms fully resolved after 4 days. CONCLUSIONS: This is the first case report, to our knowledge, describing paranoia as one of the symptoms associated with statin therapy. Our report suggests an adverse reaction due to the initiation of atorvastatin via the temporal relationship between the start of atorvastatin and symptom onset, as well as termination of therapy and subsequent symptom disappearance. Use of the Naranjo adverse drug reaction probability scale to assess causality revealed a "probable" association (score, 5) for this adverse event. This report emphasizes the possibility of paranoia as a CNS adverse effect due to statin therapy. Statins are frequently used in older populations and should therefore be considered when such CNS adverse effects occur during therapy.
Authors: Stephen P Glasser; Virginia Wadley; Suzanne Judd; Bhumika Kana; Valerie Prince; Nancy Jenny; Brett Kissela; Monika Safford; Ronald Prineas; George Howard Journal: Clin Cardiol Date: 2010-05 Impact factor: 2.882
Authors: Marco Tuccori; Francesco Lapi; Arianna Testi; Daniela Coli; Ugo Moretti; Alfredo Vannacci; Domenico Motola; Francesco Salvo; Alma Lisa Rivolta; Corrado Blandizzi; Alessandro Mugelli; Mario Del Tacca Journal: Drug Saf Date: 2008 Impact factor: 5.606
Authors: Enrica Rossini; Federico Biscetti; Maria Margherita Rando; Elisabetta Nardella; Andrea Leonardo Cecchini; Maria Anna Nicolazzi; Marcello Covino; Antonio Gasbarrini; Massimo Massetti; Andrea Flex Journal: Int J Mol Sci Date: 2022-08-18 Impact factor: 6.208